Statements (38)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2012 |
| gptkbp:ATCCode |
L01XE17
|
| gptkbp:brand |
Inlyta
|
| gptkbp:CASNumber |
319460-85-0
|
| gptkbp:chemicalClass |
indazole derivative
|
| gptkbp:contraindication |
pregnancy
|
| gptkbp:developedBy |
gptkb:Pfizer
|
| gptkbp:eliminationHalfLife |
2.5-6.1 hours
|
| gptkbp:hasMolecularFormula |
C22H18N4OS
|
| https://www.w3.org/2000/01/rdf-schema#label |
Axitinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits VEGF receptors
|
| gptkbp:metabolism |
gptkb:CYP1A2
gptkb:CYP2C19 gptkb:CYP3A4 |
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:proteinBinding |
~99%
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL521686
6450551 DB06626 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:hand-foot_syndrome
diarrhea fatigue hypertension dysphonia |
| gptkbp:target |
gptkb:VEGFR-1
gptkb:VEGFR-2 gptkb:VEGFR-3 |
| gptkbp:UNII |
32CM1I371D
|
| gptkbp:usedFor |
renal cell carcinoma
|
| gptkbp:bfsParent |
gptkb:NCT03400917
|
| gptkbp:bfsLayer |
6
|